Fluid fluctuations assessed with artificial intelligence during the maintenance phase impact anti-vascular endothelial growth factor visual outcomes in a multicentre, routine clinical care national age-related macular degeneration database
Authors:
- Ruben Martin-PinardelRMRuben Martin-Pinardel
- Jordi Izquierdo-SerraJIJordi Izquierdo-Serra
- Carolina Bernal-MoralesCBCarolina Bernal-Morales
- Sandro De ZanetSZSandro De Zanet
- Gonzaga Garay-AramburuGGGonzaga Garay-Aramburu
- Martin PuzoMPMartin Puzo
- Carolina ArruabarrenaCACarolina Arruabarrena
- Maximino AbraldesMAMaximino Abraldes
- Laura BrocLBLaura Broc
- Jose Juan Escobar-BarrancoJEJose Juan Escobar-Barranco
- 23 January 2025
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 109 (10) , 1161-1170
Abstract
Aim To evaluate the impact of fluid volume fluctuations quantified with artificial intelligence in optical coherence tomography scans during the maintenance phase and visual outcomes at 12 and 24 months in a real-world, multicentre, national cohort of treatment-naïve neovascular age-related macular degeneration (nAMD) eyes. Methods Demographics, visual acuity (VA) and number of injections were collected using the Fight Retinal Blindness tool. Intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), total fluid (TF) and central subfield thickness (CST) were quantified using the RetinAI Discovery tool. Fluctuations were defined as the SD of within-eye quantified values, and eyes were distributed according to SD quartiles for each biomarker. Results A total of 452 naïve nAMD eyes were included. Eyes with highest (Q4) versus lowest (Q1) fluid fluctuations showed significantly worse VA change (months 3–12) in IRF −3.91 versus 3.50 letters, PED −4.66 versus 3.29, TF −2.07 versus 2.97 and CST −1.85 versus 2.96 (all pConclusion This multicentre study reports a negative effect in VA outcomes of fluid volume fluctuations during the maintenance phase in specific fluid compartments, suggesting that anatomical and functional treatment response patterns may be fluid-specific.Keywords
Funding Information
- Novartis (FCRB project code CP042794)
This publication has 30 references indexed in Scilit:
- Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular DegenerationOphthalmology and Therapy, 2023
- Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep LearningOphthalmology Retina, 2021
- Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep LearningOphthalmology, 2021
- Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2021
- Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registryGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor AgentsJAMA Ophthalmology, 2020
- Application of Automated Quantification of Fluid Volumes to Anti–VEGF Therapy of Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Pathological OCT Retinal Layer Segmentation Using Branch Residual U-Shape Networks2017
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseasesGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IVOphthalmology, 2016